Evaluation of the effect of vitamin D supplementation on insulin resistance, lipid profile, thyroid function indices and body composition in overweight and obese patients with hypothyroidism and glucose intolerance

Phase 3

Recruiting

• Conditions: Condition 1: Hypothyroidism. Condition 2: Impaired glucose tolerance. Condition 3: Overweight and obesity.; Other hypothyroidism; Impaired glucose tolerance (oral); Overweight and obesity; R73.02

• Registration Number: IRCT20210630051751N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Individuals between 20 and 75 years old.
Overweight or obese individuals with a body mass index above 25.
Individuals Suffering from hypothyroidism with TSH levels higher than 7 microIU/ml.
Individuals with impaired glucose tolerance with fasting plasma glucose levels above 100 mg/dL or 2-hour plasma glucose above 140 mg / dL.
Individuals with serum 25-hydroxyvitamin D3 concentration is less than 30 ng/ml.

Exclusion Criteria

Individuals with cancer, kidney, liver, cardiovascular, bone, and endocrine diseases other than hypothyroidism and glucose intolerance disorders.
Individuals taking drugs related to diseases such as cancer, kidney, liver, heart, and drugs that affect bone metabolism (estrogen, selective estrogen receptor modulator, bisphosphonate, vitamin D, or calcium).
Individuals consuming multivitamins-minerals.
Pregnant and lactating women.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Insulin resistance: A disorder of glucose homeostasis that is defined as a decrease in the sensitivity of adipose tissue, liver, liver, and other body tissues to insulin, despite normal or elevated levels of insulin in the blood. Timepoint: At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention. Method of measurement: Using the formula HOMA-IR: [Fasting insulin(mIU/L) × fasting glucose(mg/dL)]/405.